@OncoThor @MayoCancerCare Didn't A021501 finish accrual in borderline CaPan? https://t.co/O7N68NRx4r
Great trial led by my former mentor @JoeHermanMD , along with a host of leaders in the field, helping to define an optimal neoadjuvant approach to borderline resectable pancreatic cancer
Between PREOPANC and the Alliance A021501 trial (FOLFIRINOX x 4 --> FOLFIRINOX x 4 or FOLFIRINOX x 3 + SBRT as neoadjuvant tx for borderline resectable tumors) mgmt of pancreatic adenocarcinoma is becoming just as multidisciplinary as anorectal & GE
RT @ChocolatiereP: Alliance for clinical trials in oncology trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofra…
The radiation-containing arm of A021101 (XRT coming after 7 cycles of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenoCA) has CLOSED as fewer-than-anticipated pts proceeding to an op after XRT #SWOGonc https://t.co/mmtVJBKvco
@ASTRO_org @jdsteen1 @BK_radiation @sabinbmotwanimd @NEJM An @ALLIANCE_org trial looks like for resectable patients it may be on the right track, testing FOLFIRINOX vs. mFOLFIRINOX with stereotactic radiation https://t.co/u0IJELpeEF Beyond scope of #ASCO
RT @ALLIANCE_org: Congrats to Alliance researcher Dr. Matthew H. Katz, @MDAndersonNews, for the recent activation of a phase II trial! http…
RT @ALLIANCE_org: Congrats to Alliance researcher Dr. Matthew H. Katz, @MDAndersonNews, for the recent activation of a phase II trial! http…
RT @ALLIANCE_org: Congrats to Alliance researcher Dr. Matthew H. Katz, @MDAndersonNews, for the recent activation of a phase II trial! http…
Congrats to Alliance researcher Dr. Matthew H. Katz, @MDAndersonNews, for the recent activation of a phase II trial! https://t.co/chnccwppbS